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Abstract 
The aim of this review is to summarize the effect in host energy metabolism of the production of B group vitamins 
and short chain fatty acids (SCFA) by commensal, food‑grade and probiotic bacteria, which are also actors of the 
mammalian nutrition. The mechanisms of how these microbial end products, produced by these bacterial strains, 
act on energy metabolism will be discussed. We will show that these vitamins and SCFA producing bacteria could be 
used as tools to recover energy intakes by either optimizing ATP production from foods or by the fermentation of cer‑
tain fibers in the gastrointestinal tract (GIT). Original data are also presented in this work where SCFA (acetate, butyrate 
and propionate) and B group vitamins (riboflavin, folate and thiamine) production was determined for selected 
probiotic bacteria.
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Background
It has been well established that adenosine triphos-
phate (ATP) plays a crucial role in cell biology since it 
transports within the cells the chemical energy required 
for numerous metabolic processes. When an energy 
demanding process is required, ATP is converted to 
its precursor adenosine diphosphate or adenosine 
monophosphate, and when involved in energy produc-
ing reactions, these precursors are recycled back to ATP 
as energy storage units. Needless to say, the human body 
obtains its energy from foods that contain carbohydrates, 
proteins and fatty acids which are used in different met-
abolic reactions in order to increase cellular ATP levels 
which are essential for life itself.
Aerobic organisms, such as humans, use the Krebs 
cycle (also known as the citric acid cycle or the 
tricarboxylic acid cycle), which is a series of chemical 
reactions, to obtain energy from either the metabolisms 
of glucose and/or amino acids or the degradation of fatty 
acids. These energy producing processes require the use 
of different compounds that should also be obtained 
by exogenous sources (food) such as Short Chain Fatty 
Acids (SCFA) and certain B group vitamins.
In this review, we will describe the potential beneficial 
roles of SCFA and vitamins produced by commensal, 
food-grade and probiotic bacteria. We will particularly 
emphasize the impact of these bacterial products on host 
energy metabolism and consecutively on fatigue. Our 
hypothesis is that a better regulation of the production of 
these energetic metabolites by these bacteria could help 
to salvage energy.
The human gut microbiota and host energy 
metabolism
The human gut microbiota plays a major role in the 
direct ingestion of foods but also in the mammalian 
nutrition system. Most of the absorption and digestion 
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of ingested food takes place in the gastrointestinal tract 
(GIT) where the commensal bacteria, components of the 
gut microbiota, play a very important role. One of the 
first described contributions of the commensal bacteria 
to human metabolism and physiology was their ability to 
produce vitamin B12 [1]. Afterwards, it was shown that 
they can also synthesize vitamins B and K [2]. They also 
play a role in proteins, lipids and more importantly in 
carbohydrates metabolism [3]. These commensal bacteria 
ferment carbohydrates, principally non-digestible carbo-
hydrates that are not used by the host, into  CO2,  H2 and 
 CH4 and short-chain fatty acids (SCFAs) primarily ace-
tate, propionate and butyrate [4]. Most of these SCFAs 
produced in the intestine are then absorbed by the host 
and contribute to its energy.
The commensal bacteria can also transform some 
plant-derived non-nutritional substances, such as flavo-
noids, leading to the formation of a large variety of nutri-
tional metabolites for humans [5]. In fact, the human gut 
microbiota influences the systemic metabolism of the 
host, modulating the metabolic profile of topographically 
remote organs such as the liver and the kidney [6].
Moreover, besides the commensal bacteria, transit-
ing food-grade and probiotic bacteria are also playing a 
role in host energy metabolism through the production 
of some biogenic compounds in functional foods: they 
(i) improve the nutritional composition of these foods 
in free vitamins, bioactive peptides and γ-amino butyric 
acid (GABA) [7–9] and (ii) increase the concentration of 
free amino acids and other nutritional compounds and 
metabolites [10–12]. All these commensal, food-grade 
and probiotic bacteria are interacting with the host cells 
which absorb nutrients, water and electrolytes [13]. They 
are contributing to energy production through glucose 
synthesis and degradation: neoglucogenesis and glycog-
enolysis. Neoglucogenesis is a ubiquitous process that 
results in the synthesis of glucose from non-carbohydrate 
carbon substrates such as pyruvate, lactate, glycerol, glu-
cogenic amino acids, and fatty acids. Neoglucogenesis 
and the glycogenolysis (degradation of glycogen) are the 
main mechanisms in humans to maintain an appropri-
ate level of glucose, the most important energy source for 
humans.
The role of short chain fatty acids (SCFAs) produced 
by commensal and probiotic bacteria in host 
energy intake
SCFAs produced by commensal bacteria
The non-digestible carbohydrates, including cellulose, 
xylans, resistant starch and inulin, are fermented in the 
colon by the anaerobic colonic bacteria to yield energy for 
microbial growth and end products such as SCFAs [14]. 
SCFAs have been shown to exert many positive effects on 
mammalian energy metabolism. In addition to glucose, 
mammals utilize these SCFAs (also named volatile fatty 
acids) as a metabolic fuel [15]. SCFAs, mainly acetate, pro-
pionate and butyrate [16], are essential for the health and 
wellbeing of the host when present in sufficient quantities. 
Moreover, the presence of carbohydrates (dietary fibers, 
prebiotics) is essential to orientate the metabolic activ-
ity in the direction of carbohydrates fermentation [17]. 
In fact, it has been demonstrated that 70% of the energy 
obtained by intestinal epithelial cells (IECs) is derived 
from butyrate which is mainly produced by commensal 
bacteria especially Clostridia species belonging to Fir-
micutes such as Ruminococcus and Faecalibacterium [18] 
(see Table 1).
SCFAs have been pointed out as the link between diet, 
gut microbiota, and host energy metabolism [19]. It has 
been estimated that when taken up, a large part of the 
SCFAs is used as a source of energy and this could pro-
vide nearly 10% of our daily caloric requirements [20]. 
Recently, studies with labeled SCFAs infused in mice 
have shown that 62% of infused propionate were used 
as gluconeogenic substrate in whole body glucose pro-
duction. Glucose synthesis from propionate accounted 
for 69% of total glucose production and the synthe-
sis of palmitate and cholesterol in the liver from cae-
cal acetate and butyrate as substrates while synthesis 
from propionate was low or absent [21]. All these data 
support the fact that SCFAs (acetate, propionate, and 
butyrate) produced by the human gut microbiota are 
playing important roles as substrates for glucose, cho-
lesterol, and lipids metabolism. Butyrate is the energy 
substrate for the colonic epithelium and acetate and 
propionate for peripheral tissues [19]. To better under-
stand the relationship between SCFAs and host energy 
metabolism, we need to decipher the SCFAs pathway 
and signaling, focusing on different free fatty acid (FFA) 
receptors. For instance, two FFA receptors, GPR43 and 
GPR41, have been very recently reported to regulate 
host energy homeostasis in the GIT and adipose tissues 
[15, 22]. GPR43-deficient mice are obese on a normal 
diet, whereas mice overexpressing GPR43 specifically in 
adipose tissue remain lean even when fed with a high-
fat diet [23].
The impact of all these relationships is more evident 
when the intestinal homeostasis is broken. As the gut 
microbiota affects nutrient acquisition and energy regu-
lation of the host, it can influence the development of 
obesity, insulin resistance, and diabetes [22]. In fact, obe-
sity and type 2-diabetes mellitus are characterized by a 
lower abundance of specific bacteria (such as Akkerman-
sia muciniphila and others) and SCFAs leading to gut-
barrier dysfunction, low-grade inflammation and altered 
glucose, lipid and energy homeostasis [24]. SCFAs are 
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also playing important roles in inflammation and cancer. 
It is thus interesting to mention that Faecalibacterium 
prausnitzii, the first anti-inflammatory commensal bacte-
rium identified on the basis of human clinical data, is also 
one of the major butyrate-producer of the human intesti-
nal microbiota [25, 26].
SCFAs produced by probiotic bacteria
According to the WHO/FAO, probiotics are “live micro-
organisms that, when administered in adequate amounts, 
confer a health benefit on the host”. In this sense, the 
most commonly used probiotics are lactic acid bacte-
ria (LAB) and bifidobacteria. Lactobacilli can produce 
SCFAs (i) by the fermentation of carbohydrates end-
products such as pyruvate, which is generated during the 
glycolytic pathway; and also (ii) by the phosphoketolase 
route in the heterofermenting conditions [27]. Bifido-
bacteria are using the fermentation pathway to produce 
mainly acetate and formate during growth under carbo-
hydrates limitation, and acetate and lactate when car-
bohydrates are in excess [28]. In vivo, acetate enters the 
peripheral circulation to be metabolized by muscles and 
other tissues, while propionate is taken up by the liver 
[27]. This ability to produce SCFAs by both lactobacilli 
and bifidobacteria is highlighted when the SCFAs con-
centration is analyzed under different microbiota compo-
sitions. For instance, supplementation with Lactobacillus 
salivarius ssp. salicinius JCM 1230 and L. agilis JCM 1048 
during 24 h in a simulated chicken cecum was shown to 
significantly increase propionate and butyrate formation 
[29]. L. acidophilus CRL 1014 was also recently shown to 
increase SCFAs concentration in SHIME (for Simulator 
of Human Microbial Ecosystem) reactor [30].
Growth and metabolic activity of probiotic bacteria 
such as bifidobacteria and lactobacilli, can be selectively 
stimulated by various dietary carbohydrates not digested 
by the host, called “prebiotics”. In fact, the combination 
probiotics-prebiotics (called synbiotic) is able to shift the 
predominant bacteria and the production of SCFAs of 
fecal microbiota in a model system of the human colon 
[31]. The production of SCFAs by these bacteria is poten-
tially an essential regulatory effector of epithelial prolif-
eration in the gut [32].
One of the best-characterized probiotic strain, Lacto-
bacillus rhamnosus strain GG (LGG), has been included 
in several studies with mix of probiotic strains and 
Table 1 Vitamin and short chain fatty acids (SCFA) producing bacteria
(Non exhaustive list)
Microorganism/s Type Compound References
Ruminococcus, Faecalibacterium Commensal Butyrate [18]
Bifidobacteria Probiotic Acetate/lactate [27]
L. salivarius spp salcinius JCM 1230
L. agilis JCM 1048
Probiotic Propionate/butyrate [29]
L. acidophilus CRL 1014 Probiotic Acetate/butyrate/propionate [30, 33–35]
LGG Probiotic Propionate This study
B. longum SP 07/3 Probiotic Propionate/acetate
B bifidum MF 20/5 Probiotic Propionate/acetate
L. gasseri PA 16/8 Probiotic Propionate
L. plantarum WCSF1 Comensal Folate [46]
Bifidobacteria Food‑grade Thiamin  [50, 51]
Lactococcus, Leuconostoc Food‑grade Thiamin [52]
L. sanfranciscensis Food‑grade Thiamine [53]
L. lactis Food‑grade Riboflavin [60]
L. fermentum, Food‑grade Riboflavin [61]
Leuconostoc mesenteroides and Propionibacterium freudenreichii Food‑grade Riboflavin [62–65]
L. plantarum Food‑grade Riboflavin [41]
151 LAB strains Food‑grade Folate [40]
40 LAB strains Food‑grade Folate [43]
36 LAB strains Food‑grade Folate [42]
L. fermentum CECT 5716 Probiotic Vit B2 and B9 [38]
LGG Probiotic Vit B1, B2 and B9 This study
B adolescentis DSM 18350 Probiotic Folate [83]
Page 4 of 10LeBlanc et al. Microb Cell Fact  (2017) 16:79 
prebiotics where it was able to metabolize these prebiot-
ics leading to SCFAs production.
The few available human clinical studies based on the 
production of SCFAs have been performed using a mix-
ture of probiotics and prebiotics. Note that no human 
clinical studies have been performed using any probiotic 
strain alone such as LGG in the field of SCFAs produc-
tion. Some bifidobacteria strains have been character-
ized in terms of acetate and lactate production [33–35]. 
Here, we have thus evaluated the in  vitro potential to 
produce and release de novo SCFAs of four probiotic 
bacterial strains: LGG; Bifidobacterium longum SP 07/3, 
B. bifidum MF 20/5 and L. gasseri PA 16/8. LGG was 
able to produce and release propionate in a significant 
amount (89 µM of propionate in MRS medium), but was 
not able to produce either butyrate or acetate (Fig. 1a). 
B. longum SP 07/3and B. bifidum MF 20/5 were able to 
produce and release acetate in a significant amount. B. 
longum SP 07/3, B. bifidum MF 20/5 and L. gasseri PA 
16/8were able to produce and release propionate in a sig-
nificant amount, but were not able to produce butyrate 
(Fig. 1).
SCFAs can exert multiple beneficial effects on vari-
ous aspects of mammalian energy metabolism; however, 
our understanding of the underlying molecular mecha-
nisms remains incomplete. This situation is partly due 
to the lack of human data since most of the results were 
obtained in rodents and cannot be directly translated to 
humans. Moreover, the field is severely hampered by the 
lack of data on actual fluxes of SCFAs and metabolic pro-
cesses regulated by SCFAs. Most studies report concen-
trations of metabolites (fatty acids, glucose, cholesterol, 
etc.) or transcript levels, but these do not necessarily 
reflect flux changes.
A number of questions need to be addressed: (1) what 
are the in  vivo SCFAs production and uptake fluxes 
under different conditions (i.e., with different fibers, with 
different microbiota, or in different disease models)? (2) 
How do these SCFAs then affect glucose and lipids fluxes 
via their dual role as substrates and regulators? And (3) 
does the demand of the host for specific SCFAs drive a 
change in microbial metabolism?
A quantitative and time-resolved approach to these 
questions should bring a great step forward to elucidate 
the role of SCFAs in mammalian energy metabolism. 
In this regard, Van den Abbeele et  al. [36] have shown 
the potential role of some commensal bacteria in the 
production of SCFAs [32]. Based on this scheme, we 
can consider that diet supplement containing probiotic 
lactobacilli and/or bifidobacteria can probably contrib-
ute positively to this process and thus play a role in this 
process.
The key role of vitamins produced by commensal 
and probiotic bacteria in host energy metabolism
As previously stated in the introduction, to convert 
food into ATP, the energy storing molecule, numer-
ous co-factors including B group vitamins are involved. 
Although most of these vitamins are not essential for 
Fig. 1 a Acetate and propionate production by Lactobacillus 
rhamnosus GG and L. gasseri PA 16/8, Bifidobacterium longum SP 07/3 
and B. bifidum MF 20/5in supernatant (white bars), cellular extracts 
(stripped bars) and total production (black bars). The bacterial strains 
have been grown overnight in MRS medium (plus cysteine for bifido‑
bacteria strains) at 37 °C. Cultures were then centrifuged (5000g for 
10 mn at 4 °C). Supernatants and pellets were separated and frozen 
in liquid nitrogen immediately. The error bars are SEM (Standard Error 
Mean) and the experiments were performed four times. They were 
kept at −80 °C until further analyses. Acetate, butyrate and propion‑
ate were quantified in supernatant and pellets by Mass Spectromec‑
try. b B group vitamin production by L. rhamnosus GG in supernatant 
(white bars), cellular extracts (stripped bars) and total production (black 
bars). The probiotic strain was grown in folate, riboflavin or thiamin 
free media (Difco) after which cells were centrifuged (4000×g) and 
washed with saline solution (0.85% NaCl, m/v). Folates and riboflavin 
were quantified according to previously described microbiological 
methods [41, 88] and thiamin using a Xevo Triple‑Quadrupole mass 
spectrometer (Waters Corporation) equipped with an electro‑
spray ionization interface coupled to an Acquity H‑Class UPLCTM 
device (Waters Corporation) according to Waters application notes 
LGC/R/2011/181
Page 5 of 10LeBlanc et al. Microb Cell Fact  (2017) 16:79 
each metabolic reaction, they are cofactors of enzymes 
that act as catalyzers so that the reactions can occur at 
a high enough rate to produce energy at a rate compat-
ible with life. Most B group vitamins are directly involved 
in energy metabolism and these functions. In order to 
facilitate where each vitamin acts, a schematic review of 
energy metabolism is provided in Fig. 2.
Thiamin (vitamin B1), as thiamine diphosphate (TPP), 
plays a fundamental role in host energy metabolism 
since it acts as a co-factor for enzymatic reactions that 
cleaves α-keto acids such as pyruvic acid [37]. The role 
of riboflavin in energy metabolism is even more evident 
since it is phosphorylated into Flavin Adenine Dinu-
cleotide (FAD) and acts as oxidative agents through 
its capacity to accept a pair of hydrogen atoms. It then 
catalyzes the decarboxylation of pyruvate to acetyl-CoA 
and the conversion of α-ketoglutarate to succinyl-CoA 
which is the 5th reaction of the Krebs cycle. Niacin 
(vitamin B3) in the form of Nicotinamide Adenine 
Dinucleotide (NAD) is the electron acceptor for isoci-
trate dehydrogenase, α-ketoglutarate dehydrogenase 
and malate dehydrogenase. Pantothenic acid (vitamin 
B5) is required for synthesis of coenzyme A (CoA) 
required for the pyruvate dehydrogenase complex, 
α-ketoglutarate dehydrogenase, and branched-chain 
α-ketoacid dehydrogenase. During the catabolism of 
fatty acids with an odd number of carbon atoms and 
certain amino acids (valine, isoleucine, methionine, and 
threonine), propionyl-CoA is converted to succinyl-
CoA for oxidation in the Krebs cycle through enzymes 
that requires vitamin B12 (cobalamin) or vitamin B7 
(biotin) as co-factors.
Vitamins production by commensal, food‑grade 
and probiotic bacteria
Although most LAB and bifidobacteria are considered 
auxotroph for vitamins production, there is an increas-
ing amount of evidence that certain strains of these two 
Fig. 2 Whereare microbial synthesized short‑chain fatty acids (SCFA) and B group vitamins (B1 thiamin, B2 riboflavin, B3 niacin, B5 panthothenic 
acid, B7 biotin, B12 cobalamin) involved in energy metabolism? In parenthesis are the active forms of the co‑factors involved in each reaction 
(FADH2 flavin adenine dinucleotide in hydroquinone form, CoA acetyl coenzyme A, NADH nicotinamide adenine dinucleotide, TPP thiamin pyroph‑
osphate)
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groups of bacteria can produce B-group vitamins. Micro-
organisms isolated from a variety of ecological niches 
such as the GIT of humans and other animals [2, 38, 
39], dairy products [40–42], plants [43] and grains [43], 
have been shown thus to produce varying amounts of 
vitamins B1, B2, B12 or B9. The genetic and biochemi-
cal pathways of these B group vitamins biosynthesis is 
well known [2] and will not be discussed in this review, 
but it is important to state that regardless of their origin, 
certain strains can produce elevated concentrations of 
vitamins. These vitamins are normally stored inside the 
cells and released by direct diffusion, using specific trans-
porters in the cell membrane or via cellular lysis either in 
their growth media or inside the GIT of the host, making 
these strains ideal candidates for the in situ delivery of B 
group vitamins.
Vitamins production by commensal bacteria
Although it has been suggested that some commensal 
bacterial species can synthesize essential vitamins, espe-
cially of the B and K groups [44], there are very few works 
that have been able to isolate and prove that specific com-
mensal bacteria are able to produce these vitamins and 
no data on their concentrations effectively produced in 
the GIT have been published yet. In this sense, it has been 
shown that L. plantarum WCSF1, a commensal Lactoba-
cillus strain isolated from human saliva, was shown to 
possess the folate biosynthesis genes in its genome [45] 
and that this strain can produce folate in culture media 
[46]. However, it was shown that only one genetic modi-
fication allowed this strain to produce enough of the 
vitamin to generate a methotrexate (a folate antagonist) 
resistant phenotype that is observed in high-folate pro-
ducing strains [47]. Also, it was shown that the riboflavin 
biosynthesis operon has been shown to be interrupted in 
L. plantarum WCFS1 genome resulting in its inability to 
produce riboflavin or other vitamins [45].
In a genome assessment of 256 human gut bacteria, 
it was shown that 40–65% possessed the biosynthesis 
pathways for eight B-vitamins (biotin, cobalamin, folate, 
niacin, pantothenate, pyridoxine, riboflavin, and thia-
min). However, all of the strains were not able to produce 
these vitamins in culture media [48]. These authors have 
hypothesized on the amounts of vitamins that certain 
strains could produce inside the GIT. However, these val-
ues are a very weak estimation since they are based on 
intracellular vitamin concentrations from other works 
where the strains were grown in laboratory conditions 
and do not reflect the hostile environment and substrate 
availability of the GIT.
The effects of vitamins produced by commensal bacte-
ria need to be studied further, especially the amounts of 
vitamins produced in the GIT. Besides their nutritional/
physiological properties, many of these vitamins have 
also been shown to be involved in the development and 
function of immune cells of the host since there is a 
direct link between commensal bacteria-derived vitamin 
biosynthetic intermediates and immune cells that directly 
recognize these intermediates [49].
Vitamins production by food‑grade bacteria
There are only a few studies that have shown that LAB 
or other food-grade microorganisms have the capac-
ity to produce thiamin. Strains of bifidobacteria were 
able to produce elevated concentrations of thiamin in 
soymilk and fermented milks [50, 51] as could the meso-
philic starter cultures consisting of strains of Lactococcus 
and Leuconostoc [52]. Lactobacillus sanfranciscensis iso-
lated from fermented cereals was capable of producing 
thiamine [53] and in a screening trial of 83 LAB strains 
isolated from fermented pickles, 50 were able to grow in 
thiamin free culture media but only produced very low 
concentrations of the vitamin [54]. In this sense, it was 
also shown that L. salivarius CRL1328 did not require 
thiamin for its growth [55]. The biosynthesis of thiamin 
in prokaryotes was described in detail for Escherichia 
coli, Salmonella typhimurium and Bacillus subtilis and L. 
reuteri ATCC 55,730 [56, 57]. In a recent study, L. plan-
tarum WCFS1 was shown to be able to produce thiamin 
although some of the biosynthesis genes were missing 
[48]. The metabolic pathways of this latter strain were 
further studied and for thiamin biosynthesis, initially 
3 of 10 required reactions were not coupled to a gene. 
However, it was suggested that there are orthologs such 
as MoaD and MoeEin the L. plantarum genome which 
could be involved in thiamin biosynthesis [58] and could 
explain its thiamin producing capability.
As it was the case for thiamin, there are limited studies 
that have shown that LAB or other food-grade bacteria 
can produce riboflavin, although the number of B2 pro-
ducing strains is significantly higher. As example, it was 
shown that 42 strains of LAB isolated from a variety of 
fermented dairy products were able to produce ribofla-
vin [41] as did 8 strains from goat milk and cheeses [40]. 
Moreover, roseoflavin has been used to obtain constitu-
tive riboflavin overproducing strains of B. subtilis [59], 
Lactococcus lactis [60], L. plantarum [41], L. fermentum 
[61] Leuconostoc mesenteroides and Propionibacterium 
freudenreichii [62–65]. Some of these have been shown 
to provide beneficial effects in vitamin depleted animals 
and could be inserted as novel starter cultures [66–69].
The role of folates in energy metabolism is not as direct 
as thiamin and riboflavin. Folate dependent enzymes 
are involved in the metabolism of several amino acids 
including methionine. The synthesis of this important 
amino acid is catalyzed by methionine synthase, an 
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enzyme that does not only require folate (as 5-methyl-
tetrahydrofolate) but also vitamin B12. One of the most 
important roles of folate is its involvement in the meth-
ylation cycle. In terms of energy production, the meth-
ylation cycle serves to degrade excess methionine in the 
liver to homo-cysteine, which can either be catabolized 
to sulfate and pyruvate with the latter being used for 
energy in the Krebs cycle. Because LAB produce folate, 
there has been great interest to search folate produc-
ing strains as an alternative of the use of the chemically 
synthesized folic acid that is normally used in fortifica-
tion programs and as dietary supplements that has been 
show to induce adverse side effects when consumed in 
large quantities [70]. A few recent examples of folate 
producing LAB are 151 strains isolated from goat milk 
and chesses [40], 40 from raw cereal materials [43], 36 
strains from yogurt or cheese starter cultures [42], 25 
from amaranth and 15 from quinoa (personal data). As 
is the case with all vitamins, production by LAB and 
bifodobacteria is a strain dependent trait. There are 
also reports of genetically modified strains that produce 
elevated concentrations of folates [71–74] and some of 
which have been shown to be effective in the reversion 
of folate deficiencies in mice [75, 76].
Vitamins production by probiotic bacteria
Although most vitamin producing-microorganisms 
identified so far cannot be considered probiotics 
because they lack essential studies (survival in the GIT, 
adherence to mucosal cells, evidence of their effects in 
humans clinical trials), there are promising probiotic 
strains that have been shown to be able to produce B 
group vitamins.
L. fermentum CECT5716 was originally isolated from 
human milk of healthy mothers [77] and the complete 
genome of this strain was sequenced [78]. There are 3 
clinical studies published using this strain which were 
performed to evaluate their safety [79], immune-modu-
lating properties [80], and capacity to prevent gastroin-
testinal and respiratory infections in infants [81]. This 
strain was able to produce both vitamins B2 and B9 [38] 
and the gene clusters responsible for the production of 
both vitamins were also identified. The production of 
vitamins has only been demonstrated in microbial cul-
ture media and none of the clinical trials evaluated serum 
vitamin concentrations of patients that received this 
probiotic.
L. rhamnosus GG, isolated from the GIT of a healthy 
human, is able to synthetize B1, B2 and B9 in culture 
medium (Fig. 1b). Although the synthesis levels observed 
seem to be low, animal or clinical trials should be per-
formed to evaluate its effectiveness in improving the vita-
min status of consumers. This is the only one probiotic 
strain where thiamin production has been demonstrated, 
making it an ideal candidate to increase energy metabo-
lism of consumers.
Bifidobacterium lactis BB12, isolated from dairy 
products, is the most documented probiotic since it is 
described in 300 scientific publications out of which 
more than 130 are publications of human clinical stud-
ies [82]. According to the publically available genome 
sequence, it possesses all the genes for B1 biosynthesis 
but not for B2, B6, nor B9 (search in http://www.genome.
jp/kegg/kegg2.html consulted on September 30th, 2016). 
However, there are currently no published studies to con-
firm this potential vitamin production by this strain.
B. adolescentis DSM 18350 is the first probiotic able 
to increase folate concentrations in humans [83]. In this 
pioneer study, a significant increase in fecal folate con-
centrations was observed in 13 volunteers who con-
sumed 5 × 109 CFU of the strain per day during 30 days. 
Since it is assumed that at least a portion of the folates 
produced are absorbed by the host, the fecal concentra-
tion would not strictly correlate with the total amount of 
de novo synthesized folates. Further studies need to be 
conducted in order to evaluate the effect of this strain on 
vitamins concentration in serum and red blood cells. This 
strain was first shown to be able to produce folate in cul-
ture medium [84] and then shown to enhance the folate 
status (increased plasma and liver concentrations) in rats 
[85] showing that animals studies can be a good indicator 
for beneficial effects in humans.
From a biochemical point of view, it is clear that these 
B-group vitamins are either directly or indirectly involved 
in energy metabolism and since certain LAB and bifido-
bacteria strains can produce these vitamins in very large 
amounts, there is an increasing interest in using such 
bacteria for the development of novel energy drinks or 
food supplements.
We have evaluated the in vitro potential to produce and 
release de novo vitamins B1/B2 and B9 of four probiotic 
bacterial strains: L. rhamnosus GG, B. longum SP 07/3, 
B. bifidum MF 20/5 and L. gasseri PA 16/8. L. rhamnosus 
GG was a good folate (B9) and riboflavin (B2) producer 
and releaser and a low, but significant, producer of intra-
cellular thiamin without extracellular synthesis (Fig. 1b).
B. longum and B. bifidum were low but significant pro-
ducer of intracellular thiamine (B1) without extracellular 
synthesis, but were not able to produce either folates (B9) 
either riboflavin (B2).
Discussion and conclusions
The scientific data summarized in this review indicate a 
relationship between SCFA and B group vitamins pro-
duced by commensal and probiotic bacteria and energy 
metabolism by the host.
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We propose that SCFAs and B group producing bac-
teria can increase the production of ATP; however, their 
direct impact on fatigue in human must be further evalu-
ated to understand the relationship between fatigue and 
intestinal microbiota.
Recent studies conducted on chronic fatigue syndrome 
have already suggested a role for altered intestinal micro-
biota in the pathogenesis of this disease [86, 87] and 
therapeutic efforts to modify gut microbiota could be a 
means to modulate the development and/or progression 
of this disorder [87].
A new approach could be to evaluate the relation-
ship between the ability of selected probiotics strains to 
produce energy metabolites and their impact on fatigue 
in humans. In order to evaluate the potential role of 
such metabolites in the prevention and recuperation of 
fatigue, further clinical trials are needed to (i) to deter-
mine the level of production of such metabolites in the 
gut after intake of selected probiotics strains, and (ii) 
assess and evaluate their impact on fatigue.
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